GLOWing reports on NVA237 at ERS show Novartis is set to challenge BI’s Spiriva
This article was originally published in Scrip
Executive Summary
Novartis’ Phase III data for its inhaled long-acting muscarinic receptor antagonist (LAMA), NVA237 (glycopyrronium bromide;) presented at the European Respiratory Society (ERS) congress in Amsterdam, the Netherlands, shows substantial improvement in lung in patients with moderate-to-severe COPD. With the Swiss giant having filed for market authorisation in Europe (scripintelligence.com, 27 September 2011) and set for launch in 2012, observers expect a genuine challenge to the incumbent market leader, Boehringer Ingelheim’s Spiriva.